Biotech Industry Examiner

Menu
Menu
subscribe now
Search
Dermatology’s next play: bispecifics that shut down OX40L and TNF

Dermatology’s next play: bispecifics that shut down OX40L and TNF

Pairing a T-cell co-stimulatory brake with an inflammatory workhorse is

Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up

Syngene’s Baltimore Bet: Indian Biotech’s American Ambitions and Global Supply Shake-Up

A few years ago, Emergent BioSolutions’ Bayview plant in Baltimore

The explainable aging clock regulators might actually like

The explainable aging clock regulators might actually like

The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger

The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger

Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause

Intellia’s gene-editing drug faces a liver-safety test as Phase 3 trials pause

Galapagos quits cell therapy. Europe’s CGT reckoning begins.

Galapagos quits cell therapy. Europe’s CGT reckoning begins.

The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech

The AI science factory arrives: why Lila’s $1.3bn valuation matters beyond biotech

MOST POPULAR

News

The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Dermatology’s next play: bispecifics that shut down OX40L and TNF
From Hope to Proof: How Prasad’s FDA Could Reshape Biotech Approvals

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech
Roche’s Bold Foray into Obesity Treatment: A $5.3 Billion Bet on Petrelintide
Merck KGaA in Talks to Acquire U.S. Biotech Firm SpringWorks, Valued at $4 Billion

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top